Afatinib
- Generic Name
- Afatinib
- Brand Names
- Gilotrif, Giotrif
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25ClFN5O3
- CAS Number
- 850140-72-6
- Unique Ingredient Identifier
- 41UD74L59M
- Background
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif . For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by ...
- Indication
Afatinib is a kinase inhibitor indicated as monotherapy for the first-line treatment of (a) Epidermal Growth Factor Receptor (EGFR) TKI (tyrosine kinase inhibitor)-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant EGFR mutations as detected by an FDA-approved test , and (b) adult pa...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory, metastatic squamous cell Non-small cell lung cancer
- Associated Therapies
- -
A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 94
- Registration Number
- NCT01251653
- Locations
- 🇫🇷
1200.93.33002 Boehringer Ingelheim Investigational Site, Dijon, France
🇫🇷1200.93.33001 Boehringer Ingelheim Investigational Site, Saint-Herblain cedex, France
🇫🇷1200.93.33003 Boehringer Ingelheim Investigational Site, Toulouse, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.